Mile High Labs has announced $35m in Series A funding from institutional and private equity investors.
The Colorado US-based company, which claims to be the leading cannabinoid extractor in the world, says this is the largest Series A financing in the history of the cannabis market.
Series A funding typically refers to a company’s first significant round of venture capital financing – though how exactly a company defines “first” and “significant” can differ from case to case. In this instance Mile High said it will use its Series A funding to expand production capacity of CBD extracts in order to meet increasing demand.
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Do the Novel Food regulations in Europe affect your business?
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.